- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Buy, hold, sell: Whitehaven, Endeavour, Neuren Pharmaceuticals shares | 5 | The Motley Fool Australia | ||
| Mi | Neuren Pharmaceuticals Limited reports 1H results | 1 | Seeking Alpha | ||
| Mi | NEUREN PHARMACEUTICALS LIMITED: Dividend/Distribution - NEU | - | ASX | ||
| Mi | Neuren H1 2026 slides: first dividend, record royalties, EU approval | 4 | Investing.com | ||
| Mi | Neuren Pharmaceuticals reports lower profit but launches first dividend | 1 | The Motley Fool Australia | ||
| Mi | NEUREN PHARMACEUTICALS LIMITED: Investor presentation, 26 August 2026 | 2 | ASX | ||
| Mi | NEUREN PHARMACEUTICALS LIMITED: Half Yearly Report and Accounts | 1 | ASX | ||
| Di | Neuren share price in focus after DAYBU wins EU approval for Rett syndrome | 2 | The Motley Fool Australia | ||
| NEUREN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Di | NEUREN PHARMACEUTICALS LIMITED: European Commission grants marketing authorisation for DAYBU | 2 | ASX | ||
| 21.08. | NEUREN PHARMACEUTICALS LIMITED: Neuren H1 2026 Financial Results Webinar on 26 August 2026 | 4 | ASX | ||
| 05.08. | Are Neuren Pharmaceuticals shares a buy, hold or sell after rocketing 16%? | 2 | The Motley Fool Australia | ||
| 05.08. | Wednesday's HotCopper trends: Adisyn, SciDev, Neuren Pharmaceuticals and other daily topics | 3 | The Market Online Australia | ||
| 05.08. | Lunch Wrap: ASX pops above record line as Neuren catches fire | 5 | Stockhead | ||
| 05.08. | Neuren Pharmaceuticals Reports Record Q2 DAYBUE Sales, Upgrades Full-Year Royalty Forecast | 4 | Finance News Network | ||
| 05.08. | Neuren Pharmaceuticals share price rockets: record Q2 DAYBUE sales and royalty upgrade | 2 | The Motley Fool Australia | ||
| 05.08. | NEUREN PHARMACEUTICALS LIMITED: Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded | 1 | ASX | ||
| 24.07. | NEUREN PHARMACEUTICALS LIMITED: Neuren highlights participation in PMSF Family Conference | - | ASX | ||
| 29.06. | The ASX Today: Tech leads bourse as Neuren surges on major European approval boost | 7 | The Market Online Australia | ||
| 29.06. | Monday's HotCopper trends: Comms Group, Neuren Pharma, SRJ Tech, and other daily topics | 7 | The Market Online Australia | ||
| 29.06. | Health Check: No more monkey business as European regulators approve flagship Neuren drug | 2 | Stockhead |
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANTHERA PHARMACEUTICALS | 16,020 | 0,00 % | Santhera Pharmaceuticals Holding AG: Santhera Expands Biomedica Agreement to Extend AGAMREE (Vamorolone) Distribution Across Central Asia and the Caucasus | Pratteln, Switzerland, July 13, 2026 - Santhera Pharmaceuticals (SIX: SANN) today announces an expansion of its exclusive distribution agreement with Biomedica for AGAMREE (vamorolone), extending the... ► Artikel lesen | |
| CITIUS PHARMACEUTICALS | 0,602 | -0,02 % | Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update | $7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR ®
$17 million in cash and cash equivalents as of June 30, 2026
Expanded... ► Artikel lesen | |
| MILESTONE PHARMACEUTICALS | 1,165 | 0,00 % | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients' Daily Lives and Quality of Life Between Episodes | ||
| BAYER | 48,980 | +0,39 % | Bayer-Aktie: Score 1 - Warum das Rekordurteil nichts ändert - Warren Wise Podcast | Ein Risiko weniger ist noch keine Rendite: Der Oberste US-Gerichtshof hat im langen Glyphosat-Streit zugunsten von Bayer entschieden. Die Aktie sprang daraufhin deutlich nach oben. Trotzdem steht Bayer... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 59,78 | 0,00 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 15,310 | 0,00 % | Generate Biomedicines stock price target raised to $30 by H.C. Wainwright on asthma data | ||
| KAZIA THERAPEUTICS | 13,590 | 0,00 % | Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering | SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing... ► Artikel lesen | |
| LB PHARMACEUTICALS | 47,730 | 0,00 % | H.C. Wainwright raises LB Pharmaceuticals price target to $60 | ||
| NOVO NORDISK | 39,100 | -0,74 % | JPMORGAN stuft NOVO NORDISK auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat das Kursziel für Novo Nordisk von 250 auf 275 dänische Kronen angehoben, aber die Einstufung auf "Neutral" belassen. Analyst Richard Vosser hob... ► Artikel lesen | |
| MERCK KGAA | 139,55 | +0,11 % | Milliardenmarkt Krebs: Moderna und Merck läuten die nächste Biotech-Ära ein | Ein Durchbruch in der Krebsforschung sorgt für Euphorie an der Börse. Moderna und Merck feiern einen Studienerfolg. Jetzt hoffen Anleger auf die nächste große Biotech-Rallye und neue Milliardenmärkte.... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 5,020 | 0,00 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Successfully completed human factors validation study and pharmacokinetic study for Anaphylm (dibutepinephrine) sublingual filmRemains on track to resubmit Anaphylm NDA to the FDA in Q3 2026Continues... ► Artikel lesen | |
| APNIMED | 29,850 | 0,00 % | Apnimed rises on Street initiations following IPO | ||
| ELI LILLY | 1.009,00 | -0,39 % | BioTech: Übernahmen! Der Kampf um Marktanteile bei Novo Nordisk und Eli Lilly, BioNxt und Evotec auf dem M&A-Radar | Wie die jüngste, spektakuläre 43-Milliarden-USD-Übernahme des Krebsspezialisten Seagen durch Pfizer oder die Mega-Deals rund um die GLP-1-Infrastruktur eindrucksvoll zeigen, befindet sich die Pharmabranche... ► Artikel lesen | |
| KARDIGAN | 20,020 | 0,00 % | Citi's U.S. Consumer Cards Business To Buy Kard Financial For Undisclosed Terms | WASHINGTON (dpa-AFX) - Banking major Citigroup Inc. (C) announced late Thursday that its U.S. Consumer Cards business has agreed to acquire Kard Financial, a commerce media and rewards platform.... ► Artikel lesen | |
| OMNIAB | 4,470 | 0,00 % | Veraxa Biotech AG: VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb | VXA-222 advances into next phase at VERAXAZURICH, SWITZERLAND, July 27, 2026 --
VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA" or the "Company"), an emerging leader in designing novel cancer therapies... ► Artikel lesen |
NEUREN PHARMACEUTICALS LIMITED gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 11,900 Euro und damit -4,03 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEUREN PHARMACEUTICALS LIMITED finden Sie auf Wallstreet Online.